Becton Dickinson & Co - BDX STOCK NEWS

BD (Becton, Dickinson and Company) (NYSE: BDX) has entered a co-exclusive commercial agreement with Magnolia Medical Technologies to reduce blood culture contamination in U.S. hospitals. The collaboration will promote Magnolia Medical's Steripath® Initial Specimen Diversion Device®, which is FDA-cleared to enhance testing accuracy for sepsis. This device meets the new 1% blood culture contamination guideline set by the CDC. Clinical studies support its effectiveness, with many hospitals adopting it to improve patient outcomes and reduce healthcare costs associated with contamination.

BD (NYSE: BDX) has entered into a collaboration with Biocorp to enhance self-administered drug therapies through connected technology. The partnership aims to integrate Biocorp's Injay® technology with BD's UltraSafe Plus™ Passive Needle Guard, allowing biopharmaceutical manufacturers to capture and transmit injection data. This innovation is expected to improve patient adherence to injectable drugs. The connected drug delivery market is projected to grow significantly as digital technologies and self-administered therapies become more prevalent.

BD (Becton, Dickinson and Company) will announce its fiscal 2022 fourth quarter and full year financial results on November 10, 2022, at approximately 6:30 a.m. ET. The announcement will provide summarized financial information for the quarter and full year ending on September 30, 2022.

An audio webcast will follow at 8 a.m. ET on the same day to discuss the results and company operations. Investors can access the release and the webcast on BD's investor relations website.

BD (Becton, Dickinson and Company) has announced a grant of $360,000 to six U.S. free clinics as part of its Point-of-Care, Enhancing Clinical Effectiveness initiative. This program, established in 2017, has supported 27 clinics across 20 states with a total of $2.6 million. The initiative aims to improve health outcomes in underserved communities by providing diagnostic testing capabilities for common health issues, impacting over 16,500 patient visits this year. Collaborating partners include Heart to Heart International and the National Association of Free and Charitable Clinics.

BD (Becton, Dickinson and Company) has launched the BD® Research Cloud, a cloud-based software designed to enhance flow cytometry workflows. This integrated ecosystem aids scientists in optimizing panel design, collaboration, and data analysis across various research fields like immunology and oncology. Developed by the creators of FlowJo™ Software, it streamlines the workflow by connecting instruments to data analysis, enabling more efficient experiments and faster insights. The platform is built on a reliable cloud infrastructure and aims to support future advancements in flow cytometry research.

BD announced the global availability of its new molecular PCR assay for monkeypox virus, developed in collaboration with CerTest Biotec. This assay is intended for research use only and is now accessible worldwide, including in the U.S. BD is also preparing to submit a clinical test for emergency use authorization. The BD MAX™ System, which supports this assay, features rapid nucleic acid extraction and PCR capabilities. The new test aims to enhance monkeypox research amidst the ongoing public health emergency.

LivaNova PLC (NASDAQ: LIVN) announced the appointment of Brooke Story to its Board of Directors, effective September 15, 2022. Story brings over 20 years of experience in medical technology, currently serving as Worldwide President, Integrated Diagnostic Solutions at BD (NYSE: BDX). She previously held leadership roles at Medtronic, enhancing her expertise in the industry. The Board's Chair, William Kozy, emphasized Story's capability in fostering talent and delivering economic value, which is expected to support LivaNova's growth and innovation strategies.

BD (Becton, Dickinson and Company) has launched the BD Effivax^TM Glass Prefillable Syringe, designed in collaboration with leading pharmaceutical firms. This next-generation syringe aims to enhance vaccine manufacturing efficiency by addressing critical aspects such as processability, contamination, and integrity. With about 70% of top biopharmaceutical companies relying on BD, this innovation is set to meet increasing global demand for prefillable syringes, particularly due to the growth in vaccine pipelines. Additionally, BD continues to invest $1.2 billion in enhancing its manufacturing capacity for these products.